Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7%1 The novel B7-H3-targeted antibody-drug conjugate with a dual release mechanism of the payload is based on MediLink’s proprietary TMALIN® platform, designed to maximise antitumour activity while minimising off-target toxicity2,3 Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong, and Macau across multiple tumour types, with plans to rapidly initiate global trials Tam-Peli has received U.S. FDA and China CDE Breakthrough Therapy Designations for relapsed small-cell lung cancer (SCLC)Basel, 13 September 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY)...

CALGARY, Alberta, Sept. 11, 2026 (GLOBE NEWSWIRE) — Computer Modelling Group Ltd. (“CMG” or the “Company”) announced today the voting results from its annual general meeting of shareholders (the “Meeting”) held on September 10, 2026. A total of 52,937,297 votes were represented in person or by proxy at the Meeting, constituting approximately 67.87% of the Company’s total issued and outstanding common shares as of the record date. All of the matters put forward before shareholders for consideration and approval as set out in the Company`s Management Information Circular dated July 31, 2026 (the “Circular”) were approved by the shareholders. Each of the seven director nominees was elected as a director of CMG. Detailed results of the vote are set out below.  Voted For % For VotesWithheld % WithheldALEXANDER M. DAVERN 48,058,532 97.37% 1,298,988 2.63%ANUROOP...

PITTSBURGH, Sept. 11, 2026 (GLOBE NEWSWIRE) — Axe Compute Inc. (NASDAQ: AGPU) (the “Company”) today announced that it has granted a non-qualified stock option to purchase 60,000 shares of the Company’s common stock to one non-executive individual as an inducement material to the individual’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The option was not granted under the Company’s 2024 Equity Incentive Plan. The stock option has an exercise price of $10.67 per share and a grant date of September 7, 2026. The option has a ten-year term and vests as follows: one-third of the shares subject to the option vest on the one-year anniversary of the grant date, and the remaining shares vest in equal monthly installments over the following twenty-four months, in each case subject to continued...

VANCOUVER, British Columbia, Sept. 11, 2026 (GLOBE NEWSWIRE) — Pan Global Resources Inc. (“Pan Global” or the “Company”) (TSXV: PGZ; OTCQB: PGZFF; FRA: 2EU) is pleased to announce that it has entered into an investor relations agreement (the “Agreement”) with Adelaide Capital Markets Inc. (“Adelaide”), a leading investor relations and capital markets advisory firm, to provide investor relations and consulting services to the Company. Pursuant to the Agreement, Adelaide has been engaged to provide investor marketing and communications services to the Company, including the coordination of a non-deal roadshow. The Agreement has a set term commencing on September 11, 2026, and will conclude on September 30, 2026 unless terminated in accordance with its terms. Under the Agreement, the...

DENVER, Sept. 11, 2026 (GLOBE NEWSWIRE) — EverCommerce Inc. (NASDAQ: EVCM), a company dedicated to simplifying operations and empowering growth for service SMBs, today announced that its Board of Directors has approved a $25 million increase to its previously approved $300 million share repurchase program bringing the total approved authorization to $325 million through December 31, 2027. Repurchases under the program may be made from time to time in the open market at prevailing market prices or in negotiated transactions off the market. Open market repurchases will be structured to occur within the pricing and volume requirements of Rule 10b-18. The company may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases of its shares under this authorization. This program does not obligate the company to acquire...

Anchor private-sector sponsorship helping turn Canada’s ‘Playground to Podium’ vision into actionCapital Power proposes a sponsorship of $5 million in the first year of its planned partnership with Alpine Canada, followed by up to $20 million of additional support over a proposed five-year term. The Government of Canada applauds this private-sector investment and is also announcing $2.77 million in supplemental funding for Alpine Canada building on their support to date and bringing Alpine Canada’s total funding for 2026-2027 to $8 million, which includes investments to the Whistler, Panorama and Nakiska national training centres. Alpine Canada is inviting additional Canadian winter national sport organizations to join this partnership that delivers system efficiencies putting needed resources behind athletes, coaches, clubs and communities.CALGARY,...

BEYOND THE EXTREME Digital Music Night Debuts_01.JPGThe audience enjoy the music.BEYOND THE EXTREME Digital Music Night Debuts_02.JPGAI generated the realtime music captures.BEYOND THE EXTREME Digital Music Night Debuts_03.JPGThe guests watching the e-sports show on the screen.STOCKHOLM, Sept. 11, 2026 (GLOBE NEWSWIRE) — “BEYOND THE EXTREME – An Arctic Night of Digital Art & Electronic Music,” hosted by Perfect World Digital Art, officially opened at ICEBAR by ICEHOTEL in Stockholm. Set in a fully immersive -5°C ice environment, the event brought together Chinese intangible cultural heritage (ICH), esports, and cutting-edge Al technology, creating an audiovisual experience that transcended cultural, geographical, and temporal boundaries. The event received special support from vrch.io,...

September 11, 2026 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2026 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, today announces its unaudited interim results for the six months ended June 30, 2026 which will also be made available on the Company’s website at https://biodexapharma.com/ . OPERATIONAL HIGHLIGHTS The Company announced the following in the six months ended June 30, 2026:In-license of MTX240 (formerly OPB-171755) from Otsuka Pharmaceutical Co., Limited in February 2026 with a nominal upfront payment.Launch of a global Early Access Program for eRapa for FAP Patients through a strategic partnership with Tanner Pharma Group...